Valuation: Nexentis Technologies

Market Cap 37.37L 33.51L 30.63L 27.96L 52.68L 35Cr 54.34L 3.69Cr 1.47Cr 19Cr 1.4Cr 1.37Cr 59Cr P/E 2024
-1.4x
P/E 2025 -1.68x
Enterprise Value 7L 6L 5L 5L 9L 6.18Cr 10L 64.96L 25.9L 3.3Cr 24.68L 24.15L 10Cr EV / Sales 2024
55.5x
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+6.79%
1 week-82.43%
Current month-82.43%
1 month-90.48%
3 months-94.56%
6 months-98.24%
Current year-99.13%
1 week 0.48
Extreme 0.4777
2.9
1 month 0.48
Extreme 0.4777
4.8
Current year 0.48
Extreme 0.4777
119
1 year 0.48
Extreme 0.4777
119
3 years 0.48
Extreme 0.4777
9,248.64
5 years 0.48
Extreme 0.4777
75,031.36
10 years 0.48
Extreme 0.4777
2,70,124.26
Manager TitleAgeSince
Chief Executive Officer 60 05/11/2020
Director of Finance/CFO 39 18/04/2022
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 54 26/08/2020
Chairman 62 24/05/2021
Director/Board Member 54 26/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
09/02/26 Free

Chief Financial Officer

50,000 1.8639%
09/02/26 Free

Chairman

1,16,286 4.3350%
09/02/26 Free

Chief Executive Officer

1,00,000 3.7279%

Financials

2024 2025
Net sales 2L 2L 2L 2L 3L 1.97Cr 3L 20.75L 8L 1.05Cr 8L 8L 3.33Cr -
Net income -51.93L -46.58L -42.57L -38.86L -73.21L -49Cr -75.52L -5.13Cr -2.05Cr -26Cr -1.95Cr -1.91Cr -82Cr -40.04L -35.91L -32.82L -29.96L -56.45L -38Cr -58.23L -3.96Cr -1.58Cr -20Cr -1.5Cr -1.47Cr -63Cr
Net Debt -24.85L -22.29L -20.37L -18.59L -35.03L -23Cr -36.14L -2.46Cr -97.9L -12Cr -93.27L -91.27L -39Cr -30.79L -27.62L -25.24L -23.04L -43.41L -29Cr -44.77L -3.04Cr -1.21Cr -15Cr -1.16Cr -1.13Cr -49Cr
Projected Income Statement - Annual - Nexentis Technologies
Logo Nexentis Technologies
Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.
Employees
8
Sector
-
Date Price Change Volume
06/26/06 $2.571 +6.79% 45,841
05/26/05 $2.408 -13.24% 38,707
04/26/04 $2.775 -2.46% 13,410
03/26/03 $2.845 +7.08% 9,795
02/26/02 $2.657 -9.21% 11,631
  1. Stock Market
  2. Stocks
  3. NXTS Stock